Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImmuCellFRA:IUL +1.22%58 Net Debt Paydown Yield % is 2.05% as of Aug. 20, 2026. GuruFocus rates FRA:IUL with a GF Score™ of 58/100 and a GF Value™ of €5.66 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,154 Biotechnology companies, ImmuCell ranks better than 80.59% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, ImmuCell's Net Debt Paydown Yield % was 2.05%.
ImmuCell (FRA:IUL) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
The historical data trend for ImmuCell's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:IUL vs COYA, ENTX, BDTX: Net Debt Paydown Yield % Comparison
For the Biotechnology subindustry, ImmuCell's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImmuCell Net Debt Paydown Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ImmuCell's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where ImmuCell's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 2.05% mean?
ImmuCell (FRA:IUL) has a Net Debt Paydown Yield % of 2.05% as of Aug. 20, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on ImmuCell and its competitors. According to the industry distribution chart, ImmuCell ranks #224 out of 1154 companies in the Biotechnology industry, placing it in the top 19.4%.
Is ImmuCell's Net Debt Paydown Yield % too high?
ImmuCell's current Net Debt Paydown Yield % is 2.05%. The Biotechnology industry median Net Debt Paydown Yield % is 0.03. ImmuCell's value of 2.05% is 6733.3% above this industry median. Based on the distribution chart, ImmuCell ranks #224 out of 1154 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ImmuCell has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ImmuCell's Net Debt Paydown Yield % compare to COYA and ENTX?
According to the Biotechnology industry distribution chart, ImmuCell ranks #224 out of 1154 companies for Net Debt Paydown Yield %. This places ImmuCell in the top 19% of its industry — outperforming the majority of peers. The industry median Net Debt Paydown Yield % is 0.03. ImmuCell's value of 2.05% is 6733.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.03, based on 1,154 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ImmuCell's current Net Debt Paydown Yield % of 2.05% is 6733.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on ImmuCell and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ImmuCell's current Net Debt Paydown Yield % is 2.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuCell stock overvalued right now?
Based on GuruFocus' analysis, ImmuCell (FRA:IUL) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.66, compared to a current price of €8.30 — trading 46.6% above its estimated fair value. The current Net Debt Paydown Yield % is 2.05% and 6733.3% above the Biotechnology industry median of 0.03. ImmuCell's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For ImmuCell (FRA:IUL), the current Net Debt Paydown Yield % is 2.05% as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ImmuCell (FRA:IUL) Overvalued in 2026?
Based on GuruFocus' analysis, ImmuCell stock appears to be overvalued.
The current stock price of €8.30 is trading 46.6% above its estimated GF Value™ of €5.66.
GuruFocus considers ImmuCell to be Significantly Overvalued.
Key valuation signals for FRA:IUL:
Net Debt Paydown Yield %: 2.05%
GF Value™: €5.66 vs. price of €8.30 (46.6% above fair value)
Industry Position: 6733.3% above the Biotechnology median (#224 of 1154)
No single metric tells the full story. See the FRA:IUL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
58GF Score
Get the complete analysis for FRA:IUL
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IUL has been successfully added to your 
